An investigational therapy is demonstrating preclinical promise against non-Hodgkin lymphoma by boosting natural killer cells ...

PHILADELPHIA, PA — Vittoria Biotherapeutics, Inc. has announced the launch of its Phase 1 clinical trial for VIPER-101, a ...

By studying mutations in malignant T cells that cause lymphoma, they zeroed ... How Gene Activity Modulates the Amount of Immune Cell Production in Mice Jan. 26, 2024 — Researchers describe how ...

Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects the skin. Here authors show that CDK9 degradation of retinoic acid receptor α is a vulnerability for CTCL and ...

SAN DIEGO — Mantle cell lymphoma patients who go into deep remission from a first therapy may not get any benefit from a follow-up transplant of their stem cells, according to a new study.

Jenna had been diagnosed with lymphoma in 2020 and, after relapsing post-chemotherapy, she hoped a personalized treatment option called CAR T cell therapy would be the answer. “I didn’t know ...

Scientists have discovered that our specialized immune cells, called T cells, are what they eat -- their switch from functional to 'exhausted' depends on the switch from metabolizing acetate to ...

Many are needed to fight cancer. The CAR T cells are specific to the patient’s cancer. For example, some types of lymphoma ...

At the recent American Society of Hematology annual meeting, early data from the Mithic-FL1 Trial demonstrated impressive ...

CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable. There have been a number of advancements in the treatment of follicular lymphoma in 2024.

The marginal zone lymphoma trial is unique in that most clinical trials don't separate out patients with this type of cancer because it is relatively rare, comprising only 6 to 8% of non-Hodgkin ...